Designing a combined Liothyronine (LT3), L-thyroxine (LT4) trial in symptomatic hypothyroid subjects on LT4 – the importance of patient selection, choice of LT3 and trial design

Premawardhana, Lakdasa D., Taylor, Peter Nicholas ORCID: https://orcid.org/0000-0002-3436-422X, Okosieme, Onwebuchi E., Adlan, Mohamed A., Obuobie, Emmanuel K. and Dayan, Colin Mark ORCID: https://orcid.org/0000-0002-6557-3462 2023. Designing a combined Liothyronine (LT3), L-thyroxine (LT4) trial in symptomatic hypothyroid subjects on LT4 – the importance of patient selection, choice of LT3 and trial design. Frontiers in Endocrinology 14 , 1282608. 10.3389/fendo.2023.1282608

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (671kB) | Preview

Abstract

Approximately 10%–15% of subjects with hypothyroidism on L-thyroxine (LT4) alone have persistent symptoms affecting their quality of life (QoL). Although the cause is unclear, there is evidence that “tissue T3 lack” may be responsible. If so, combining liothyronine (LT3) with LT4 would be helpful. However, randomized controlled trials (RCT), have not established greater efficacy for the LT3 + LT4 combination in these subjects than for LT4 alone. While the trial design may have been responsible, the use of unphysiological, short-acting LT3 preparations and non-thyroid-specific patient-reported outcome measures (PROMs) may have contributed. We recommend attention to the following aspects of trial design for future RCTs of LT3 + LT4 compared to LT4 alone: (a) Subject selection—(i) measurable symptoms (disadvantages should be recognized); (ii) using a validated thyroid specific PROM such as ThyPRO39 or the Composite scale derived from it; (iii) those taking over 1.2 μg/day or 100 μg/day (for pragmatic reasons) of LT4 defining a population likely without intrinsic thyroid activity who depend on exogenous LT4; (iv) recruiting a preponderance of subjects with autoimmune thyroiditis increasing generalisability; and (v) those with a high symptom load with a greater response to combination therapy e.g. those with the deiodinase 2 polymorphism. (b) The use of physiological LT3 preparations producing pharmacokinetic similarities to T3 profiles in unaffected subjects: two long-acting LT3 preparations are currently available and must be tested in phase 2b/3 RCTs. (c) The superiority of a crossover design in limiting numbers and costs while maintaining statistical power and ensuring that all subjects experienced the investigative medication.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Systems Immunity Research Institute (SIURI)
Publisher:	Frontiers Media
ISSN:	1664-2392
Date of First Compliant Deposit:	8 November 2023
Date of Acceptance:	23 October 2023
Last Modified:	20 Dec 2023 14:36
URI:	https://orca.cardiff.ac.uk/id/eprint/163708

Actions (repository staff only)

Edit Item